← Back to Search

IDECIDE-HOSPICE for Hospice Care Awareness

N/A

Waitlist Available

Led By Channing E Tate, PhD, MPH

Research Sponsored by University of Colorado, Denver

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Must not have

Have a cognitive impairment that prevents them from providing informed consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up june 2023 through september 2023

Awards & highlights

No Placebo-Only Group

Summary

This trial will ask older Black adults about what they know and think about hospice care.

Who is the study for?

This clinical trial is for older Black adults to explore their understanding and attitudes towards hospice care. Specific eligibility criteria are not provided, so it's important to contact the study organizers for detailed information on who can participate.

What is being tested?

The intervention being tested in this trial is called IDECIDE-HOSPICE, which likely involves educational or decision-making aids designed to inform participants about hospice care options.

What are the potential side effects?

Since this study seems focused on gathering information rather than testing a medical treatment, there may be no direct physical side effects from participation. Emotional discomfort discussing end-of-life care could occur.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am unable to understand and give consent for medical procedures due to cognitive impairment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ june 2023 through september 2023

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~june 2023 through september 2023

This trial's timeline: 3 weeks for screening, Varies for treatment, and june 2023 through september 2023 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Hospice Beliefs and Attitudes

Hospice Knowledge

Self-Efficacy

Secondary study objectives

Medical Mistrust

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: InterviewExperimental Treatment1 Intervention

20 of the 200 Intervention participants will complete an interview using qualitative methods surrounding the topic of hospice care and the PtDA.

Group II: InterventionExperimental Treatment1 Intervention

200 participants reviewed the PtDA decision tool for education on hospice care and subsequently completed a second survey which was identical to the first.

Group III: ControlActive Control1 Intervention

200 of the 400 participants completed two identical surveys one month apart but did NOT review the PtDA decision tool prior to completing the second survey timepoint. Instead, these participants reviewed an 8-page attention control activity booklet. These participants are used as a control group in assessing any change in knowledge or opinions of hospice after the intervention group reviewed the PtDA.

0 / 1Eligibility criteria met